Cognizant (CTSH) Q4 Earnings Beat Estimates, Revenues Down Y/Y

Cognizant Technology Solutions CTSH reported fourth-quarter 2023 non-GAAP earnings of $1.18 per share, which beat the Zacks Consensus Estimate by 13.46% and increased 16.8% year over year.

Revenues of $4.76 billion lagged the consensus mark by 0.08%. The top line decreased 1.7% year over year and 2.4% at constant currency (cc). Acquisitions contributed 90 basis points (bps) to top-line growth.

Cognizant’s fourth-quarter results suffered from a challenging macroeconomic environment, cautious clients and limited discretionary spending

Bookings decreased 6% year over year. Cognizant’s fourth-quarter bookings included seven deals that exceeded $100 million each. Of these seven deals, two were new business and five were a mix of renewals and expansions.

Cognizant Technology Solutions Corporation Price, Consensus and EPS Surprise

Cognizant Technology Solutions Corporation Price, Consensus and EPS Surprise

Cognizant Technology Solutions Corporation price-consensus-eps-surprise-chart | Cognizant Technology Solutions Corporation Quote

On a trailing twelve-month basis, bookings increased 9% year over year to $26.3 billion, which represented a book-to-bill of approximately 1.4 times.

Top-Line Details

Financial services revenues (29.3% of revenues) decreased 5.8% year over year (down 6.6% at cc) to $1.395 billion. The decline was attributed to a challenging demand environment.

Health Sciences revenues (29.3% of revenues) declined 2.1% year over year (down 2.7% at cc) to $1.396 billion. Soft discretionary spending negatively impacted top-line growth.

Products and Resources revenues (24.4% of revenues) increased 1.9% year over year (up 0.6% at cc) to $1.16 billion. The segment benefited from acquisitions.

Communications, Media and Technology revenues (16.9% of revenues) were $804 million, which increased 2.6% from the year-ago quarter (up 2% at cc). The segment benefited from new acquisitions and the ramp of new bookings.

Region-wise, revenues from North America decreased 1.6% year over year (down 1.7% at cc) and accounted for 74.2% of total revenues.

Revenues from Europe increased 1.3% from the year-ago quarter (down 3.4% at cc) and made up 19.3% of total revenues. Revenues from the U.K. decreased 1.1% (down 5.8% at cc). Continental Europe revenues increased 3.8% (down 1% at cc).

The Rest of the World revenues decreased 9.9% year over year (down 7.9% at cc) and represented 6.5% of total revenues.

Operating Details

Selling, general & administrative expenses, as a percentage of revenues, decreased 130 bps year over year to 16.5%.

Total headcount at the end of the fourth quarter was 347,700, down 7,600 year over year but up 1,100 sequentially.

Voluntary attrition - Tech Services for the year ended Dec 31, 2023, declined to 13.8% from 25.6% for the year ended Dec 31, 2022.

Cognizant reported a GAAP operating margin of 15.2%, up 100 bps on a year-over-year basis.

The company incurred $40 million in costs related to the NextGen program, negatively impacting the GAAP operating margin by 90 bps.

Non-GAAP operating margin (adjusted for NextGen charges) of 16.1% expanded 190 bps year over year.

Balance Sheet

Cognizant had cash and short-term investments of $2.64 billion as of Dec 31, 2023 compared with $2.37 billion as of Sep 30, 2023.

As of Dec 31, 2023, the company had a total debt of $639 million, down from $647 million reported as of Sep 30, 2023.

It generated $737 million in cash from operations compared with $828 million in the previous quarter.

Free cash flow was $659 million compared with free cash flow of $755 million reported in the prior quarter.

In the fourth quarter of 2023, the company returned $298 million through share repurchases. As of Dec 31, 2023, it had $1.8 billion remaining under the current share repurchase program.

Cognizant raised its dividend payout by 3% year over year to 30 cents per share, payable on Feb 28 to shareholders of record Feb 20.


Cognizant expects first-quarter 2024 revenues between $4.68 billion and $4.76 billion, indicating a decline of 2.7% to 1.2% (a decline of 3-1.5% on a cc basis).

In the Financial Services segment, Cognizant continues to expect the challenging macro environment to hurt spending rates, thereby negatively impacting top-line growth.

For 2024, revenues are expected to be $19-$19.8 billion, indicating a decline of 1.8% to growth of 2.2% on a reported basis (down 2% to growth of 2% on a cc basis). Acquisitions are expected to contribute 100 bps and 20 bps positive impact from favorable forex.

Adjusted operating margin for 2024 is expected to be between 15.3% and 15.5%. Adjusted earnings for 2024 are expected between $4.50 and $4.68 per share.

Moreover, it still expects to incur $300 million in NextGen charges, out of which $70 million will be recognized in 2024.

Cognizant expects to return $1 billion to shareholders through share repurchases (at least $400 million) and regular quarterly dividends.

Zacks Rank & Other Stocks to Consider

The company currently carries a Zacks Rank #3 (Hold).

Shopify SHOP, Pinterest PINS and AvidXchange AVDX are some better-ranked stocks that investors can consider in the broader sector, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Shopify shares have gained 4.2% year to date. SHOP is set to report its fourth-quarter 2023 results on Feb 13.

Pinterest shares have gained 6% year to date. PINS is set to report its fourth-quarter 2023 results on Feb 8.

AvidXchange shares have declined 6.5% year to date. AVDX is set to report its fourth-quarter 2023 results on Feb 28.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.

It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Cognizant Technology Solutions Corporation (CTSH) : Free Stock Analysis Report

Shopify Inc. (SHOP) : Free Stock Analysis Report

AvidXchange Holdings, Inc. (AVDX) : Free Stock Analysis Report

Pinterest, Inc. (PINS) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.